Merck (MRK) announces that the US FDA has accepted a sBLA for ENFLONSIA to expand its indication to include prevention of RSV lower respiratory tract disease in children under two years of age at increased risk for severe RSV disease

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.